Corbus Pharmaceuticals (NASDAQ:CRBP) Posts Earnings Results, Misses Estimates By $0.54 EPS

Corbus Pharmaceuticals (NASDAQ:CRBP) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.54), FiscalAI reports.

Corbus Pharmaceuticals Stock Performance

CRBP stock traded up $0.20 during midday trading on Wednesday, reaching $4.12. 180,349 shares of the company’s stock traded hands, compared to its average volume of 546,995. The firm has a market capitalization of $77.02 million, a PE ratio of -0.67 and a beta of 2.80. The company has a 50-day moving average price of $6.14 and a two-hundred day moving average price of $8.43. Corbus Pharmaceuticals has a 52 week low of $2.81 and a 52 week high of $12.88.

Analyst Ratings Changes

Several brokerages recently weighed in on CRBP. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Corbus Pharmaceuticals in a report on Monday, September 14th. Wall Street Zen downgraded shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Thursday, October 15th. Mizuho set a $33.00 target price on shares of Corbus Pharmaceuticals in a research report on Thursday, August 13th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Corbus Pharmaceuticals in a research note on Wednesday. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.57.

Trending Headlines about Corbus Pharmaceuticals

Here are a few of the latest headlines about CRBP:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $35 price target, issuing 2027 quarterly EPS estimates that anticipate continued losses. The bullish rating and target are a positive signal, though the estimates underscore ongoing costs. Corbus Pharmaceuticals coverage
• Negative Sentiment: Corbus reported a Q3 2026 loss of $1.81 per share, missing analysts’ estimate of a $1.27 loss by $0.54. The earnings miss may weigh on investor sentiment. Q3 results and corporate update

Insider Activity at Corbus Pharmaceuticals

In other news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the firm’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $4.10, for a total value of $1,742,500.00. Following the completion of the transaction, the insider directly owned 1,919,971 shares of the company’s stock, valued at $7,871,881.10. This trade represents a 18.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.50% of the stock is owned by insiders.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease. Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.